11-62338027-A-G
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_001083926.2(ASRGL1):c.50A>G(p.Lys17Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000106 in 1,608,020 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_001083926.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ASRGL1 | NM_001083926.2 | c.50A>G | p.Lys17Arg | missense_variant | 2/7 | ENST00000415229.6 | NP_001077395.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ASRGL1 | ENST00000415229.6 | c.50A>G | p.Lys17Arg | missense_variant | 2/7 | 1 | NM_001083926.2 | ENSP00000400057 | P1 | |
ENST00000400902.4 | n.64T>C | non_coding_transcript_exon_variant | 1/2 | 4 |
Frequencies
GnomAD3 genomes AF: 0.0000788 AC: 12AN: 152218Hom.: 0 Cov.: 34
GnomAD3 exomes AF: 0.0000127 AC: 3AN: 236856Hom.: 0 AF XY: 0.00000778 AC XY: 1AN XY: 128598
GnomAD4 exome AF: 0.00000343 AC: 5AN: 1455684Hom.: 0 Cov.: 32 AF XY: 0.00000138 AC XY: 1AN XY: 723616
GnomAD4 genome AF: 0.0000788 AC: 12AN: 152336Hom.: 0 Cov.: 34 AF XY: 0.0000805 AC XY: 6AN XY: 74490
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | May 08, 2024 | The c.50A>G (p.K17R) alteration is located in exon 2 (coding exon 1) of the ASRGL1 gene. This alteration results from a A to G substitution at nucleotide position 50, causing the lysine (K) at amino acid position 17 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 20, 2023 | This sequence change replaces lysine, which is basic and polar, with arginine, which is basic and polar, at codon 17 of the ASRGL1 protein (p.Lys17Arg). This variant is present in population databases (rs543873786, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with ASRGL1-related conditions. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at